| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis
|
Parihar, Akshay
|
|
|
28 |
10 |
p.
|
artikel
|
| 2 |
Advancements in small molecule drug design: A structural perspective
|
Wu, Ke
|
|
|
28 |
10 |
p.
|
artikel
|
| 3 |
Advancing novel therapies for neurodegeneration through an innovative model for industry–academia collaborations: A decade of the Eisai–UCL experience
|
Atkinson, Peter J.
|
|
|
28 |
10 |
p.
|
artikel
|
| 4 |
Analysis of pharma R&D productivity – a new perspective needed
|
Schuhmacher, Alexander
|
|
|
28 |
10 |
p.
|
artikel
|
| 5 |
Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery
|
Xu, Liang
|
|
|
28 |
10 |
p.
|
artikel
|
| 6 |
Building a nonclinical pathology laboratory of the future for pharmaceutical research excellence
|
Rudmann, D.G.
|
|
|
28 |
10 |
p.
|
artikel
|
| 7 |
Call for next-generation drugs that remove the uptake barrier to combat antibiotic resistance
|
Peng, Bo
|
|
|
28 |
10 |
p.
|
artikel
|
| 8 |
Causal inference in drug discovery and development
|
Michoel, Tom
|
|
|
28 |
10 |
p.
|
artikel
|
| 9 |
Comparison and summary of in silico prediction tools for CYP450-mediated drug metabolism
|
Zhai, Jingchen
|
|
|
28 |
10 |
p.
|
artikel
|
| 10 |
Contents page
|
|
|
|
28 |
10 |
p.
|
artikel
|
| 11 |
Critical path activities in clinical trial setup and conduct: How to avoid bottlenecks and accelerate clinical trials
|
Bieske, Linn
|
|
|
28 |
10 |
p.
|
artikel
|
| 12 |
3D printing combined with biopredictive dissolution and PBPK/PD modeling optimization and personalization of pharmacotherapy: Are we there yet?
|
Wyszogrodzka-Gaweł, Gabriela
|
|
|
28 |
10 |
p.
|
artikel
|
| 13 |
Human serum albumin binders: A piggyback ride for long-acting therapeutics
|
Ullah, Aziz
|
|
|
28 |
10 |
p.
|
artikel
|
| 14 |
Immunogenicity risk assessment of synthetic peptide drugs and their impurities
|
De Groot, Anne S
|
|
|
28 |
10 |
p.
|
artikel
|
| 15 |
Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases
|
Enya, Kazuaki
|
|
|
28 |
10 |
p.
|
artikel
|
| 16 |
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?
|
Sharma, Arun K
|
|
|
28 |
10 |
p.
|
artikel
|
| 17 |
Learning from COVID-19: How drug hunters can prepare for the next pandemic
|
Puhl, Ana C.
|
|
|
28 |
10 |
p.
|
artikel
|
| 18 |
Metabolomics and lipidomics strategies in modern drug discovery and development
|
Astarita, Giuseppe
|
|
|
28 |
10 |
p.
|
artikel
|
| 19 |
Metabophore-mediated retro-metabolic (‘MeMeReMe’) approach in drug design
|
Balaji, Seetharaman
|
|
|
28 |
10 |
p.
|
artikel
|
| 20 |
Models and approaches to comprehend and address glial inflammation following spinal cord injury
|
Patil, Vaibhav
|
|
|
28 |
10 |
p.
|
artikel
|
| 21 |
Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019
|
Alsamil, Ali M.
|
|
|
28 |
10 |
p.
|
artikel
|
| 22 |
Recent advances towards overcoming the blood–brain barrier
|
Ali, Amna
|
|
|
28 |
10 |
p.
|
artikel
|
| 23 |
Regulatory benefit–risk assessment of oncology drugs: A systematic review of FDA and EMA approvals
|
Pinto, Cathy Anne
|
|
|
28 |
10 |
p.
|
artikel
|
| 24 |
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy
|
Dwivedi, Samarth
|
|
|
28 |
10 |
p.
|
artikel
|
| 25 |
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends
|
Coimbra, Judite R.M.
|
|
|
28 |
10 |
p.
|
artikel
|
| 26 |
Toward responsible clinical n-of-1 strategies for rare diseases
|
Defelippe, Victoria M.
|
|
|
28 |
10 |
p.
|
artikel
|
| 27 |
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures
|
Bieske, Linn
|
|
|
28 |
10 |
p.
|
artikel
|
Tijdschrift beschrijving